Document:

Form of February 2004 Series D Warrant

 Exhibit 4.4 
  
 THIS WARRANT AND THE SECURITIES ISSUABLE UPON THE EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
“SECURITIES ACT”), OR ANY STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED IN THE ABSENCE OF A REGISTRATION STATEMENT IN EFFECT WITH RESPECT TO THE SECURITIES UNDER THE
SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED OR UNLESS SOLD PURSUANT TO AN EXEMPTION TO THE SECURITIES ACT. 
  
 THE SALE OF THE SECURITIES WHICH ARE THE SUBJECT OF THIS WARRANT HAS NOT BEEN QUALIFIED WITH THE COMMISSIONER OF CORPORATIONS OF THE STATE
OF CALIFORNIA OR ANY OTHER STATE AND THE ISSUANCE OF SUCH SECURITIES OR THE PAYMENT OR RECEIPT OF ANY PART OF THE CONSIDERATION FOR SUCH SECURITIES PRIOR TO SUCH QUALIFICATION IS UNLAWFUL, UNLESS THE SALE OF SUCH SECURITIES IS EXEMPT FROM
QUALIFICATION BY SECTION 2511, 25102 OR 25105 OF THE CALIFORNIA CORPORATIONS CODE OR SUCH PROVISIONS OF THE CORPORATIONS CODE OF ANY SUCH OTHER STATE. THE RIGHTS OF THE HOLDER OF THIS WARRANT ARE EXPRESSLY CONDITIONED UPON SUCH QUALIFICATION BEING
OBTAINED, UNLESS THE SALE IS SO EXEMPT. 
  
 Void after 

February 27, 2011 
  
 WARRANT TO PURCHASE SHARES 
 OF PREFERRED STOCK 
  
 of 
  
 SKINMEDICA, INC. 
  
 INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE 
  
 THIS CERTIFIES THAT, for value received,
                    , together with its permitted successors and assigns (“Holder”) is entitled, subject to the terms
set forth below, to subscribe for and purchase shares of Series D Preferred Stock (the “Preferred Stock”) of SKINMEDICA, INC., a Delaware corporation (the
“Company”), subject to adjustment as provided herein. This warrant and any warrant subsequently issued upon exchange or transfer hereof are hereinafter referred to collectively as the “Warrant.”

  
 This Warrant is subject to the following terms and conditions:

  
 1. Stock Purchase Agreement. This Warrant is issued in
connection with that certain Series D Preferred Stock Purchase Agreement dated February 27, 2004 (the “Purchase Agreement”) by and among the Company and the persons listed on Schedule 1.1. thereto. All capitalized terms used
but not defined in this Warrant shall have the meanings ascribed thereto in the Purchase Agreement. 
  
 2. Exercise of Warrant. The terms and conditions upon which this Warrant may be exercised, and the shares covered hereby may be purchased, are as
follows: 
  
 2.1 Term. Subject to the terms hereof, this
Warrant may be exercised at any time after the date hereof, or from time to time, in whole or in part; provided, however, that in no event may this Warrant be exercised (the “Exercise Date”) later than 5:00 p.m. (Pacific
Time) on the close of business on February 27, 2011 (the “Exercise Period”). 
  

 1 

 2.2 Number of New Preferred Stock Shares. This Warrant may be exercised for
             shares of Preferred Stock (the “New Preferred Stock Shares”), subject to adjustment as provided herein. 
  
 2.3 Exercise Price. The “Exercise Price” shall
be equal to $2.39, subject to adjustment as provided herein. 
  
 2.4 Method of Exercise. Subject to the terms and conditions contained herein and while this Warrant remains outstanding and exercisable, from and after the date hereof, this Warrant is exercisable with respect to any or all New
Preferred Stock Shares, at the option of Holder, upon surrender of this Warrant to the Company together with (a) a duly completed (i) Notice of Exercise, in the form attached hereto as Exhibit A, or (ii) Net Issue Election Notice, in the form
attached hereto as Exhibit B and (b) payment of an amount equal to the Exercise Price multiplied by the number of New Preferred Stock Shares with respect to which this Warrant is being exercised as provided in Section 2.5 below. If Holder
exercises this Warrant with respect to less than all of the New Preferred Stock Shares represented by this Warrant, the Company shall cancel this Warrant upon the surrender thereof and shall execute and deliver to Holder a new Warrant for the
balance of such New Preferred Stock Shares. 
  
 2.5
Payment. Payment of the Exercise Price for the New Preferred Stock Shares with respect to which this Warrant is being exercised by Holder shall be made, at the option of Holder, (a) by delivery of cash payable by wire transfer of immediately
available funds, (b) by the delivery of a cashier’s check or certified check, (c) by net issue election as set forth in Section 2.6 below, or (d) by any combination of (a) – (c). 
  
 2.6 Net Issue Election Holder may elect to receive, without payment by
Holder of any additional consideration, New Preferred Stock Shares equal to the value of the “spread” on the New Preferred Stock Shares or any portion thereof by the surrender of the Warrant to the Company, together with a duly completed
Net Issue Election Notice, in the form attached hereto as Exhibit B, at the principal office of the Company, in which event the Company shall issue to Holder such number of New Preferred Stock Shares as is computed using the following
formula: 
  
 X = Y (A – B) 
           A 
  

					
	Where:	    	X =	    	The number of New Preferred Stock Shares to be issued to Holder pursuant to the net issue election;
			
	 	    	Y =	    	The number of New Preferred Stock Shares in respect of which the net issue election is made;
			
	 	    	A =	    	The fair market value (as determined below) of one New Preferred Stock Shares at the time the net issue election is made;
			
	 	    	B =	    	The Exercise Price in effect under this Warrant as of the date of the net issue election.

  

 2 

 For purposes of this Section 2.6, the fair market value of one New Preferred Stock Share as of a particular date shall be
mutually determined in good faith by the Board of Directors of the Company. In the event the Holder disagrees with the Board of Directors’ determination of such fair market value, the Holder shall provide written notice thereof to the Company
(the “Appraisal Notice”), and the valuation shall be made by an appraiser of recognized standing selected by the Company and the Holder or, if they cannot agree on an appraiser within twenty (20) days after delivery of the
Appraisal Notice, each shall select an appraiser of recognized standing and the two (2) appraisers shall designate a third (3rd) appraiser of recognized standing, whose appraisal shall be determinative of such value. The cost of such appraisal shall be shared equally by the Holder and the Company. 
  
 3. Adjustment of Exercise Price and Number of Shares. The Exercise Price and the number of New Preferred Stock Shares
purchasable upon the exercise of this Warrant shall be subject to adjustment from time to time upon the happening of certain events as follows: 
  
 3.1 Conversion of New Preferred Stock Shares into Common Stock. Upon conversion of all of the issued and outstanding shares of the Company’s
Preferred Stock into Common Stock (“Common Stock”), this Warrant shall be automatically exercisable only for such number of shares of Common Stock as Holder would have received had this Warrant been exercised in full for the
New Preferred Stock Shares and then converted into Common Stock on the date all issued and outstanding shares of the Company’s Preferred Stock converted into Common Stock. The Exercise Price in effect immediately prior to such conversion shall,
concurrently with the effectiveness of such conversion, be proportionally adjusted, and until such time as the Company has completed an initial public offering of its Common Stock, the adjusted Exercise Price shall be adjusted from to time to time
in accordance with Article IV, Section 5(f) of the Company’s Restated Certificate of Incorporation in connection with any issuance or sale by the Company of any “Additional Shares of Common Stock” (as such term is defined in the
Restated Certificate of Incorporation) at a price pr share less than the adjusted Exercise Price. Upon such conversion of the Preferred Stock into Common Stock, all references under this Warrant to New Preferred Stock Shares shall be deemed
references to Common Stock. 
  
 3.2 Split, Subdivision
or Combination. If the Company should at any time or from time to time fix a record date for (a) the effectuation of a split or subdivision of the outstanding New Preferred Stock Shares or (b) the determination of Holders of New Preferred Stock
Shares entitled to receive a dividend or other distribution payable in additional New Preferred Stock Shares or other securities or rights convertible into, or entitling Holder thereof to receive directly or indirectly, additional New Preferred
Stock Shares (hereinafter referred to as the “New Preferred Stock Equivalents”), without payment of any consideration by such holder for the additional New Preferred Stock Shares or New Preferred Stock Equivalents, then, as
of such record date (or the date of such distribution, split or subdivision if no record date is fixed), the Exercise Price shall be appropriately decreased and the number of New Preferred Stock Shares which this Warrant is exercisable for, if any,
shall be appropriately increased in proportion to such increase of outstanding shares. Notwithstanding the foregoing, in any such case, the aggregate purchase price payable by Holder for the total number of New Preferred Stock Shares (as adjusted)
shall remain the same. 
  

 3 

 3.3 Combination of Shares. If the number of New Preferred Stock Shares outstanding at any time
after the date hereof is decreased by a combination of the outstanding New Preferred Stock Shares, the Exercise Price shall be appropriately increased and the number of New Preferred Stock Shares for which this Warrant is exercisable, if any, shall
be appropriately decreased in proportion to such decrease in outstanding shares. Notwithstanding the foregoing, in any such case, the aggregate purchase price payable by Holder for the total number of New Preferred Stock Shares (as adjusted) shall
remain the same. 
  
 3.4 Reclassification or
Reorganization. If the New Preferred Stock Shares shall be changed into the same or different number of shares of any class or classes of stock, whether by capital reorganization, reclassification or otherwise (other than a subdivision,
conversion or combination of shares or stock dividend provided for in Sections 3.1, 3.2 and 3.3 above), then and in each such event Holder shall be entitled to receive upon the exercise of this Warrant the kind and amount of shares of stock and
other securities and property receivable upon such reorganization, reclassification or other change, to which a holder of the number of New Preferred Stock Shares (or any shares of stock or other securities which may be) issuable upon the exercise
of this Warrant would have received if this Warrant had been exercised immediately prior to such reorganization, reclassification or other change, all subject to further adjustment as provided herein. At the request of Holder, this Warrant will
thereupon be cancelled and upon its surrender to the Company, the Company will execute and deliver at its expense a new Warrant reflecting the foregoing adjustment, but otherwise identical to the replaced Warrant. 
  
 3.5 Notice of Adjustments and Record Dates. The Company shall promptly
notify Holder in writing of each adjustment or readjustment of the Exercise Price hereunder and the number of New Preferred Stock Shares issuable upon the exercise of this Warrant. Such notice shall state the adjustment or readjustment and show in
reasonable detail the facts on which that adjustment or readjustment is based. In the event of any taking by the Company of a record of holders of New Preferred Stock Shares for the purpose of determining holders thereof who are entitled to receive
any dividend or other distribution, the Company shall notify Holder in writing of such record date at least twenty (20) days prior to the date specified therein. 
  
 3.6 Fractional Shares. No fractional shares shall be issued upon the exercise of this Warrant as a consequence of any
adjustment pursuant hereto. All Equity Shares (including fractions) issuable upon exercise of this Warrant may be aggregated for purposes of determining whether the exercise would result in the issuance of a fractional share. If, after aggregation,
the exercise would result in the issuance of a fractional share, the Company shall, in lieu of issuance of any fractional share, pay Holder otherwise entitled to such fraction a sum in cash equal to the product resulting from multiplying the then
current fair market value of a New Preferred Stock Shares by such fraction. 
  
 3.7 Issue Tax. The issuance of certificates for the New Preferred Stock Shares upon exercise of this Warrant shall be made without charge to Holder for any issuance tax in respect thereof provided that the
Company shall not be required to pay any tax which may be payable in respect of any transfer involved in the issuance and delivery of any certificate in a name other than that of Holder. 
  

 4 

 3.8 No Impairment. The Company shall not avoid or seek to avoid the observance or performance of
any of the terms to be observed or performed hereunder by the Company, but shall at all times in good faith assist in the carrying out of all the provisions of this Warrant. Without limiting the generality of the foregoing, the Company shall take
all such action as may be necessary or appropriate in order that all shares of New Preferred Stock Shares as may be issued pursuant to the exercise of this Warrant shall, upon issuance, be duly and validly issued, fully paid and nonassessable and
free from all taxes, liens and charges with respect to the issue thereof. 
  
 3.9 Anti-Dilution Adjustment. For the avoidance of doubt, if at any time after the date of issuance of this Warrant there is an adjustment to the Series D Conversion Price pursuant to the Company’s
Restated Certificate of Incorporation, or if no Preferred Shares are then outstanding, there would have been an adjustment if any such shares were outstanding, then the New Preferred Stock Shares issued upon exercise of this Warrant shall receive
the benefit of any such adjustment to the Series D Conversion Price upon the execution of this Warrant as if the holder thereof held the New Preferred Stock Shares issued upon exercise of this Warrant at the time of such adjustment. 
  
 4. Replacement of Warrants. On receipt by the Company of evidence
reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant and, in the case of any such loss, theft or destruction of this Warrant, on delivery of an indemnity agreement reasonably satisfactory in form and
amount to the Company or, in the case of any such mutilation, on surrender and cancellation of such Warrant, the Company at its expense shall execute and deliver to Holder, in lieu thereof, a new Warrant of like tenor. 
  
 5. No Rights or Liability as a Stockholder. This Warrant does not
entitle Holder hereof to any voting rights or other rights as a stockholder of the Company. No provisions hereof, in the absence of affirmative action by Holder to purchase New Preferred Stock Shares, and no enumeration herein of the rights or
privileges of Holder, shall give rise to any liability of Holder as a shareholder of the Company. 
  
 6. Miscellaneous. 
  
 6.1 Limitations on Disposition. 
  
 6.1.1 Holder, by acceptance hereof, agrees to comply in all respects with the provisions of this Section 6.1. Holder agrees not to make any disposition
of this Warrant or any New Preferred Stock Shares, unless and until the transferee has agreed in writing for the benefit of the Company to be bound by this Section 6.1 and the other provisions of this Warrant as if such transferee were the original
Holder hereof, provided and to the extent such provisions are then applicable, and: 
  
 6.1.2 There is then in effect a registration statement under the Securities Act covering such proposed disposition and such disposition is made in accordance with such registration statement; or 
  

 5 

 6.1.3 (A) Holder shall have notified the Company of the proposed disposition and shall have furnished
the Company with a detailed statement of the circumstances surrounding the proposed disposition, and (B) if reasonably requested by the Company, Holder shall have furnished the Company with an opinion of counsel, reasonably satisfactory to the
Company, that such disposition will not require registration of the Warrant and/or the New Preferred Stock Shares under the Securities Act. It is agreed that the Company will not require opinions of counsel for transactions made pursuant to Rule 144
except in unusual circumstances. 
  
 6.2 Permitted
Transfers. Notwithstanding the provisions of paragraphs 6.1.1, 6.1.2 and 6.1.3 above, (i) no such registration statement, prior consent or opinion of counsel shall be necessary for a transfer (A) by Holder if Holder is a partnership to a partner
of such partnership or a retired partner of such partnership who retires after the date hereof, or to the estate of any such partner or retired partner or to the transfer by gift, will or intestate succession of any partner to his spouse or to the
siblings, lineal descendants, including adopted children, or ancestors of such partner or his spouse, or (B) to an “affiliate” of Holder as that term is defined in Rule 405 promulgated by the Securities and Exchange Commission under the
Securities Act, including, without limitation, a family trust or other estate vehicle of Holder or a member of Holder’s immediate family, if the transferee agrees in writing to be subject to the terms hereof to the same extent as if it were an
original Holder hereunder, and (ii) no transferee shall be required, as a condition to any transfer of the Warrant or the New Preferred Stock Shares by Holder, to agree to be bound by this Section 6.2, if the transferee is acquiring the Warrant
and/or New Preferred Stock Shares pursuant to a Registration Statement under the Securities Act or in a transaction made pursuant to Rule 144. Each new certificate evidencing the Warrant and/or New Preferred Stock Shares so transferred shall bear
the appropriate restrictive legends, except that such certificate shall not bear such restrictive legend if, in the opinion of counsel for the Company, such legend is not required in order to establish or assist in compliance with any provisions of
the Securities Act or any applicable state securities laws. 
  
 7.
Titles and Subtitles. The titles and subtitles used in this Warrant are for convenience only and are not to be considered in construing or interpreting this Warrant. 
  
 8. Notices. All notices and other communications under this Warrant shall be in writing and shall be deemed given
upon receipt if delivered personally, or when sent if mailed by registered or certified mail (return receipt requested) or by reputable overnight express courier (charges prepaid) or transmitted by facsimile (with confirmation of transmittal) to the
party to be notified at the address indicated for such party on the signature page hereof, or at such other address as such party may designate by advance written notice to the other parties. 
  
 9. Attorneys’ Fees. If any action at law or in equity is
necessary to enforce or interpret the terms of this Warrant, the prevailing party shall be entitled to reasonable attorneys’ fees, costs and disbursements in addition to any other relief to which such party may be entitled. 
  
 10. Amendments and Waivers. This Warrant may be amended and the
observance of any other term of this Warrant may be waived (either generally or in a particular instance and either retroactively or prospectively), with the written consent of the Company and the holder of this Warrant. 
  

 6 

 11. Severability. If one or more provisions of this Warrant are held to be unenforceable under
applicable law, such provision shall be excluded from this Warrant and the balance of the Warrant shall be interpreted as if such provision were so excluded and shall be enforceable in accordance with its terms. 
  
 12. Governing Law. This Warrant shall be governed by and construed and
enforced in accordance with the laws of the State of California, without giving effect to its conflicts of laws principles. 
  
 [SIGNATURE PAGE FOLLOWS] 
  

 7 

 This Warrant may be executed in one or more counterparts, each of which shall be deemed an original, but
all of which together shall constitute one and the same instrument. 
  

					
	 Date: February 27, 2004
	 	 SKINMEDICA, INC.,
 a Delaware corporation

			
	 	 	 By:
	 	  

	 	 	 	 	 Rex Bright, President and Chief
 Executive Officer

			
	 	 	 Address:
	 	 5909 Sea Lion Place, Suite H

	 	 	 	 	 Carlsbad, CA 92008

	 	 	 	 	 Facsimile No.: (760) 448-3601

  
 ACKNOWLEDGED AND AGREED: 

 

			
		
	 By:
	 	  

	 	 	 Name:

	 	 	 Title: 

	
	 Address:

	 	 	 
	 	 	 
	 	 	 

  
 SKINMEDICA, INC. 
 SERIES D PREFERRED STOCK
WARRANT 
 SIGNATURE PAGE 

 EXHIBIT A 
  

FORM OF NOTICE OF EXERCISE 
  
 The undersigned, the holder of the within Warrant, hereby irrevocably elects to exercise this Warrant for, and to purchase thereunder,
             New Preferred Stock Shares (as defined in the attached Warrant)* of SKINMEDICA, INC., a Delaware corporation and
herewith makes payment of $                 therefor and requests that the certificates for such shares be issued in the name of, and delivered to,
                    , federal taxpayer identification number
                , whose address is
                                    . 
  
 In exercising this Warrant, the undersigned hereby confirms and acknowledges
that the                  New Preferred Stock Shares (as defined in the attached Warrant) are being acquired solely for the account of the undersigned and not as
a nominee for any other party, and for investment, and the undersigned will not offer, sell or otherwise dispose of any such New Preferred Stock Shares except under circumstances that will not result in a violation of the Securities Act of 1933, as
amended, or any state securities laws. 
  
 Please issue a new
Warrant for the unexercised portion of the attached Warrant in the name of, and delivered to,                     , federal taxpayer
identification number             , whose address is
                                    . 
  
 Dated:
                     
  

	
	  
  

	 (Signature must conform to name of holder
 as specified on the face of the Warrant)

	*	Insert here the number of shares as to which the Warrant is being exercised. 

  

 A-1 

 EXHIBIT B 
  

FORM OF NET ISSUE ELECTION NOTICE 
  
 (To be signed only on net issue exercise of the Warrant) 
  
 The undersigned, the holder of the within Warrant, hereby irrevocably elects to exercise this Warrant with respect to
                 New Preferred Stock Shares (as defined in the attached Warrant) of SKINMEDICA, INC., a
Delaware corporation, pursuant to the net issue election provisions set forth in Section 2.6 of the Warrant and requests that the certificates for the number of New Preferred Stock Shares issuable pursuant to said Section 2.6 after application of
the net issue election formula to such New Preferred Stock Shares be issued in the name of, and delivered to,
                        , federal taxpayer identification number
            , whose address is
                                . 
  
 In exercising this Warrant, the undersigned hereby confirms and acknowledges
that the New Preferred Stock Shares are being acquired solely for the account of the undersigned and not as a nominee for any other party, and for investment, and the undersigned will not offer, sell or otherwise dispose of any such New Preferred
Stock Shares except under circumstances that will not result in a violation of the Securities Act of 1933, as amended, or any state securities laws. 
  
 Please issue a new Warrant for the unexercised portion of the attached Warrant in the name of, and delivered to,
                        , federal taxpayer identification number
            , whose address is
                                        
                            . 
  
 Dated:                     

  

	
	  
  

	 (Signature must conform to name of holder
 as specified on the face of the Warrant)

  

 B-1 

 Schedule to Exhibit 4.4: 
  
 The preceding form of Preferred Stock warrant was issued to the following entities and individuals in the following amounts listed below: 
  

			
	 Name

	  	Number of Shares

	 Perseus-Soros Biopharmaceutical Fund, LP
	  	334,895
	 Apax Excelsior VI, L.P.
	  	226,470
	 Apax Excelsior VI-A C.V.
	  	18,499
	 Apax Excelsior VI-B C.V.
	  	12,324
	 Patricof Private Investment Club III, L.P.
	  	7,739
	 Domain Partners V, L.P.
	  	258,916
	 DP V Associates, L.P.
	  	6,116
	 St. Paul Venture Capital VI, LLC
	  	89,305
	 Stephens Inc., Custodian for the James Gilstrap IRA
	  	18,838
	 Hale Family Trust UTD 2/10/86
	  	2,791
	 Jaffe Investment Group, LLC
	  	6,309
	 Mark G. Rubin
	  	1,668
	 The Bright Family Trust Dated February 28, 2003
	  	279Form of July 2004 Series D Warrant

 Exhibit 4.5 
  
 THIS WARRANT AND THE SECURITIES ISSUABLE UPON THE EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
“SECURITIES ACT”), OR ANY STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED IN THE ABSENCE OF A REGISTRATION STATEMENT IN EFFECT WITH RESPECT TO THE SECURITIES UNDER THE
SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED OR UNLESS SOLD PURSUANT TO AN EXEMPTION TO THE SECURITIES ACT. 
  
 THE SALE OF THE SECURITIES WHICH ARE THE SUBJECT OF THIS WARRANT HAS NOT BEEN QUALIFIED WITH THE COMMISSIONER OF CORPORATIONS OF THE STATE
OF CALIFORNIA OR ANY OTHER STATE AND THE ISSUANCE OF SUCH SECURITIES OR THE PAYMENT OR RECEIPT OF ANY PART OF THE CONSIDERATION FOR SUCH SECURITIES PRIOR TO SUCH QUALIFICATION IS UNLAWFUL, UNLESS THE SALE OF SUCH SECURITIES IS EXEMPT FROM
QUALIFICATION BY SECTION 2511, 25102 OR 25105 OF THE CALIFORNIA CORPORATIONS CODE OR SUCH PROVISIONS OF THE CORPORATIONS CODE OF ANY SUCH OTHER STATE. THE RIGHTS OF THE HOLDER OF THIS WARRANT ARE EXPRESSLY CONDITIONED UPON SUCH QUALIFICATION BEING
OBTAINED, UNLESS THE SALE IS SO EXEMPT. 
  

			
	 	 	Void after
	WDII-        	 	July 9, 2011

  
 WARRANT TO PURCHASE
SHARES 
 OF PREFERRED STOCK 
  
 of 
  
 SKINMEDICA, INC. 
  
 INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE 
  
 THIS CERTIFIES THAT, for value received,                             , together with
its permitted successors and assigns (“Holder”) is entitled, subject to the terms set forth below, to subscribe for and purchase shares of Series D Preferred Stock (the “Preferred Stock”) of
SKINMEDICA, INC., a Delaware corporation (the “Company”), subject to adjustment as provided herein. This warrant and any warrant subsequently issued upon exchange or
transfer hereof are hereinafter referred to collectively as the “Warrant.” 
  
 This Warrant is subject to the following terms and conditions: 
  

1. Stock Purchase Agreement. This Warrant is issued in connection with that certain Series D Preferred Stock Purchase Agreement dated July 9,
2004 (the “Purchase Agreement”) by and among the Company and the persons listed on Schedule 1.1. thereto. All capitalized terms used but not defined in this Warrant shall have the meanings ascribed thereto in the Purchase
Agreement. 
  
 2. Exercise of Warrant. The terms and
conditions upon which this Warrant may be exercised, and the shares covered hereby may be purchased, are as follows: 
  
 2.1 Term. Subject to the terms hereof, this Warrant may be exercised at any time after the date hereof, or from time to time, in whole or in part;
provided, however, that in no event may this Warrant be exercised (the “Exercise Date”) later than 5:00 p.m. (Pacific Time) on the close of business on July 9, 2011 (the “Exercise Period”). 

 

 2.2 Number of New Preferred Stock Shares. This Warrant may be exercised for
                 shares of Preferred Stock (the “New Preferred Stock Shares”), subject to adjustment as provided herein. 
  
 2.3 Exercise Price. The “Exercise Price” shall
be equal to $2.39, subject to adjustment as provided herein. 
  
 2.4 Method of Exercise. Subject to the terms and conditions contained herein and while this Warrant remains outstanding and exercisable, from and after the date hereof, this Warrant is exercisable with respect to any or all New
Preferred Stock Shares, at the option of Holder, upon surrender of this Warrant to the Company together with (a) a duly completed (i) Notice of Exercise, in the form attached hereto as Exhibit A, or (ii) Net Issue Election Notice, in the form
attached hereto as Exhibit B and (b) payment of an amount equal to the Exercise Price multiplied by the number of New Preferred Stock Shares with respect to which this Warrant is being exercised as provided in Section 2.5 below. If Holder
exercises this Warrant with respect to less than all of the New Preferred Stock Shares represented by this Warrant, the Company shall cancel this Warrant upon the surrender thereof and shall execute and deliver to Holder a new Warrant for the
balance of such New Preferred Stock Shares. 
  
 2.5
Payment. Payment of the Exercise Price for the New Preferred Stock Shares with respect to which this Warrant is being exercised by Holder shall be made, at the option of Holder, (a) by delivery of cash payable by wire transfer of immediately
available funds, (b) by the delivery of a cashier’s check or certified check, (c) by net issue election as set forth in Section 2.6 below, or (d) by any combination of (a) – (c). 
  
 2.6 Net Issue Election Holder may elect to receive, without payment by
Holder of any additional consideration, New Preferred Stock Shares equal to the value of the “spread” on the New Preferred Stock Shares or any portion thereof by the surrender of the Warrant to the Company, together with a duly completed
Net Issue Election Notice, in the form attached hereto as Exhibit B, at the principal office of the Company, in which event the Company shall issue to Holder such number of New Preferred Stock Shares as is computed using the following
formula: 
  
 X = Y (A – B) 
           A 
  

					
	 Where:
	  	                    X =	  	The number of New Preferred Stock Shares to be issued to Holder pursuant to the net issue election;
			
	 	  	Y =	  	The number of New Preferred Stock Shares in respect of which the net issue election is made;
			
	 	  	A =	  	The fair market value (as determined below) of one New Preferred Stock Shares at the time the net issue election is made;
			
	 	  	B =	  	The Exercise Price in effect under this Warrant as of the date of the net issue election.

  

 2 

 For purposes of this Section 2.6, the fair market value of one New Preferred Stock Share as of a particular date shall be
mutually determined in good faith by the Board of Directors of the Company. In the event the Holder disagrees with the Board of Directors’ determination of such fair market value, the Holder shall provide written notice thereof to the Company
(the “Appraisal Notice”), and the valuation shall be made by an appraiser of recognized standing selected by the Company and the Holder or, if they cannot agree on an appraiser within twenty (20) days after delivery of the
Appraisal Notice, each shall select an appraiser of recognized standing and the two (2) appraisers shall designate a third (3rd) appraiser of recognized standing, whose appraisal shall be determinative of such value. The cost of such appraisal shall be shared equally by the Holder and the Company. 
  
 3. Adjustment of Exercise Price and Number of Shares. The Exercise Price and the number of New Preferred Stock Shares
purchasable upon the exercise of this Warrant shall be subject to adjustment from time to time upon the happening of certain events as follows: 
  
 3.1 Conversion of New Preferred Stock Shares into Common Stock. Upon conversion of all of the issued and outstanding shares of the Company’s
Preferred Stock into Common Stock (“Common Stock”), this Warrant shall be automatically exercisable only for such number of shares of Common Stock as Holder would have received had this Warrant been exercised in full for the
New Preferred Stock Shares and then converted into Common Stock on the date all issued and outstanding shares of the Company’s Preferred Stock converted into Common Stock. The Exercise Price in effect immediately prior to such conversion shall,
concurrently with the effectiveness of such conversion, be proportionally adjusted, and until such time as the Company has completed an initial public offering of its Common Stock, the adjusted Exercise Price shall be adjusted from to time to time
in accordance with Article IV, Section 5(f) of the Company’s Restated Certificate of Incorporation in connection with any issuance or sale by the Company of any “Additional Shares of Common Stock” (as such term is defined in the
Restated Certificate of Incorporation) at a price pr share less than the adjusted Exercise Price. Upon such conversion of the Preferred Stock into Common Stock, all references under this Warrant to New Preferred Stock Shares shall be deemed
references to Common Stock. 
  
 3.2 Split, Subdivision
or Combination. If the Company should at any time or from time to time fix a record date for (a) the effectuation of a split or subdivision of the outstanding New Preferred Stock Shares or (b) the determination of Holders of New Preferred Stock
Shares entitled to receive a dividend or other distribution payable in additional New Preferred Stock Shares or other securities or rights convertible into, or entitling Holder thereof to receive directly or indirectly, additional New Preferred
Stock Shares (hereinafter referred to as the “New Preferred Stock Equivalents”), without payment of any consideration by such holder for the additional New Preferred Stock Shares or New Preferred Stock Equivalents, then, as
of such record date (or the date of such distribution, split or subdivision if no record date is fixed), the Exercise Price shall be appropriately decreased and the number of New Preferred Stock Shares which this Warrant is exercisable for, if any,
shall be appropriately increased in proportion to such increase of outstanding shares. Notwithstanding the foregoing, in any such case, the aggregate purchase price payable by Holder for the total number of New Preferred Stock Shares (as adjusted)
shall remain the same. 
  

 3 

 3.3 Combination of Shares. If the number of New Preferred Stock Shares outstanding at any time
after the date hereof is decreased by a combination of the outstanding New Preferred Stock Shares, the Exercise Price shall be appropriately increased and the number of New Preferred Stock Shares for which this Warrant is exercisable, if any, shall
be appropriately decreased in proportion to such decrease in outstanding shares. Notwithstanding the foregoing, in any such case, the aggregate purchase price payable by Holder for the total number of New Preferred Stock Shares (as adjusted) shall
remain the same. 
  
 3.4 Reclassification or
Reorganization. If the New Preferred Stock Shares shall be changed into the same or different number of shares of any class or classes of stock, whether by capital reorganization, reclassification or otherwise (other than a subdivision,
conversion or combination of shares or stock dividend provided for in Sections 3.1, 3.2 and 3.3 above), then and in each such event Holder shall be entitled to receive upon the exercise of this Warrant the kind and amount of shares of stock and
other securities and property receivable upon such reorganization, reclassification or other change, to which a holder of the number of New Preferred Stock Shares (or any shares of stock or other securities which may be) issuable upon the exercise
of this Warrant would have received if this Warrant had been exercised immediately prior to such reorganization, reclassification or other change, all subject to further adjustment as provided herein. At the request of Holder, this Warrant will
thereupon be cancelled and upon its surrender to the Company, the Company will execute and deliver at its expense a new Warrant reflecting the foregoing adjustment, but otherwise identical to the replaced Warrant. 
  
 3.5 Notice of Adjustments and Record Dates. The Company shall promptly
notify Holder in writing of each adjustment or readjustment of the Exercise Price hereunder and the number of New Preferred Stock Shares issuable upon the exercise of this Warrant. Such notice shall state the adjustment or readjustment and show in
reasonable detail the facts on which that adjustment or readjustment is based. In the event of any taking by the Company of a record of holders of New Preferred Stock Shares for the purpose of determining holders thereof who are entitled to receive
any dividend or other distribution, the Company shall notify Holder in writing of such record date at least twenty (20) days prior to the date specified therein. 
  
 3.6 Fractional Shares. No fractional shares shall be issued upon the exercise of this Warrant as a consequence of any
adjustment pursuant hereto. All Equity Shares (including fractions) issuable upon exercise of this Warrant may be aggregated for purposes of determining whether the exercise would result in the issuance of a fractional share. If, after aggregation,
the exercise would result in the issuance of a fractional share, the Company shall, in lieu of issuance of any fractional share, pay Holder otherwise entitled to such fraction a sum in cash equal to the product resulting from multiplying the then
current fair market value of a New Preferred Stock Shares by such fraction. 
  
 3.7 Issue Tax. The issuance of certificates for the New Preferred Stock Shares upon exercise of this Warrant shall be made without charge to Holder for any issuance tax in respect thereof provided that the
Company shall not be required to pay any tax which may be payable in respect of any transfer involved in the issuance and delivery of any certificate in a name other than that of Holder. 
  

 4 

 3.8 No Impairment. The Company shall not avoid or seek to avoid the observance or performance of
any of the terms to be observed or performed hereunder by the Company, but shall at all times in good faith assist in the carrying out of all the provisions of this Warrant. Without limiting the generality of the foregoing, the Company shall take
all such action as may be necessary or appropriate in order that all shares of New Preferred Stock Shares as may be issued pursuant to the exercise of this Warrant shall, upon issuance, be duly and validly issued, fully paid and nonassessable and
free from all taxes, liens and charges with respect to the issue thereof. 
  
 3.9 Anti-Dilution Adjustment. For the avoidance of doubt, if at any time after the date of issuance of this Warrant there is an adjustment to the Series D Conversion Price pursuant to the Company’s
Restated Certificate of Incorporation, or if no Preferred Shares are then outstanding, there would have been an adjustment if any such shares were outstanding, then the New Preferred Stock Shares issued upon exercise of this Warrant shall receive
the benefit of any such adjustment to the Series D Conversion Price upon the execution of this Warrant as if the holder thereof held the New Preferred Stock Shares issued upon exercise of this Warrant at the time of such adjustment. 
  
 4. Replacement of Warrants. On receipt by the Company of evidence
reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant and, in the case of any such loss, theft or destruction of this Warrant, on delivery of an indemnity agreement reasonably satisfactory in form and
amount to the Company or, in the case of any such mutilation, on surrender and cancellation of such Warrant, the Company at its expense shall execute and deliver to Holder, in lieu thereof, a new Warrant of like tenor. 
  
 5. No Rights or Liability as a Stockholder. This Warrant does not
entitle Holder hereof to any voting rights or other rights as a stockholder of the Company. No provisions hereof, in the absence of affirmative action by Holder to purchase New Preferred Stock Shares, and no enumeration herein of the rights or
privileges of Holder, shall give rise to any liability of Holder as a shareholder of the Company. 
  
 6. Miscellaneous. 
  
 6.1 Limitations on Disposition. 
  
 6.1.1 Holder, by acceptance hereof, agrees to comply in all respects with the provisions of this Section 6.1. Holder agrees not to make any disposition
of this Warrant or any New Preferred Stock Shares, unless and until the transferee has agreed in writing for the benefit of the Company to be bound by this Section 6.1 and the other provisions of this Warrant as if such transferee were the original
Holder hereof, provided and to the extent such provisions are then applicable, and: 
  
 6.1.2 There is then in effect a registration statement under the Securities Act covering such proposed disposition and such disposition is made in accordance with such registration statement; or 
  

 5 

 6.1.3 (A) Holder shall have notified the Company of the proposed disposition and shall have furnished
the Company with a detailed statement of the circumstances surrounding the proposed disposition, and (B) if reasonably requested by the Company, Holder shall have furnished the Company with an opinion of counsel, reasonably satisfactory to the
Company, that such disposition will not require registration of the Warrant and/or the New Preferred Stock Shares under the Securities Act. It is agreed that the Company will not require opinions of counsel for transactions made pursuant to Rule 144
except in unusual circumstances. 
  
 6.2 Permitted
Transfers. Notwithstanding the provisions of paragraphs 6.1.1, 6.1.2 and 6.1.3 above, (i) no such registration statement, prior consent or opinion of counsel shall be necessary for a transfer (A) by Holder if Holder is a partnership to a partner
of such partnership or a retired partner of such partnership who retires after the date hereof, or to the estate of any such partner or retired partner or to the transfer by gift, will or intestate succession of any partner to his spouse or to the
siblings, lineal descendants, including adopted children, or ancestors of such partner or his spouse, or (B) to an “affiliate” of Holder as that term is defined in Rule 405 promulgated by the Securities and Exchange Commission under the
Securities Act, including, without limitation, a family trust or other estate vehicle of Holder or a member of Holder’s immediate family, if the transferee agrees in writing to be subject to the terms hereof to the same extent as if it were an
original Holder hereunder, and (ii) no transferee shall be required, as a condition to any transfer of the Warrant or the New Preferred Stock Shares by Holder, to agree to be bound by this Section 6.2, if the transferee is acquiring the Warrant
and/or New Preferred Stock Shares pursuant to a Registration Statement under the Securities Act or in a transaction made pursuant to Rule 144. Each new certificate evidencing the Warrant and/or New Preferred Stock Shares so transferred shall bear
the appropriate restrictive legends, except that such certificate shall not bear such restrictive legend if, in the opinion of counsel for the Company, such legend is not required in order to establish or assist in compliance with any provisions of
the Securities Act or any applicable state securities laws. 
  
 7.
Titles and Subtitles. The titles and subtitles used in this Warrant are for convenience only and are not to be considered in construing or interpreting this Warrant. 
  
 8. Notices. All notices and other communications under this Warrant shall be in writing and shall be deemed given
upon receipt if delivered personally, or when sent if mailed by registered or certified mail (return receipt requested) or by reputable overnight express courier (charges prepaid) or transmitted by facsimile (with confirmation of transmittal) to the
party to be notified at the address indicated for such party on the signature page hereof, or at such other address as such party may designate by advance written notice to the other parties. 
  
 9. Attorneys’ Fees. If any action at law or in equity is
necessary to enforce or interpret the terms of this Warrant, the prevailing party shall be entitled to reasonable attorneys’ fees, costs and disbursements in addition to any other relief to which such party may be entitled. 
  
 10. Amendments and Waivers. This Warrant may be amended and the
observance of any other term of this Warrant may be waived (either generally or in a particular instance and either retroactively or prospectively), with the written consent of the Company and the holder of this Warrant. 
  

 6 

 11. Severability. If one or more provisions of this Warrant are held to be unenforceable under
applicable law, such provision shall be excluded from this Warrant and the balance of the Warrant shall be interpreted as if such provision were so excluded and shall be enforceable in accordance with its terms. 
  
 12. Governing Law. This Warrant shall be governed by and construed and
enforced in accordance with the laws of the State of California, without giving effect to its conflicts of laws principles. 
  
 [SIGNATURE PAGE FOLLOWS] 
  

 7 

 This Warrant may be executed in one or more counterparts, each of which shall be deemed an original, but
all of which together shall constitute one and the same instrument. 
  

					
	Date: July 9, 2004	 	 SKINMEDICA, INC.,
 a Delaware
corporation

			
	 	 	By:	 	  

			
	 	 	Address:	 	5909 Sea Lion Place, Suite H
	 	 	 	 	Carlsbad, CA 92008
	 	 	 	 	Facsimile No.: (760) 448-3601

  

			
	ACKNOWLEDGED AND AGREED:
		
	By:	 	 
		
	By:	 	  

			
		
	Address:	 	 

  
  
 SKINMEDICA, INC. 
 SERIES D
PREFERRED STOCK WARRANT 
 SIGNATURE PAGE 
  

 EXHIBIT A 
  

FORM OF NOTICE OF EXERCISE 
  
 The undersigned, the holder of the within Warrant, hereby irrevocably elects to exercise this Warrant for, and to purchase thereunder,
                     New Preferred Stock Shares (as defined in the attached Warrant)* of SKINMEDICA,
INC., a Delaware corporation and herewith makes payment of $                 therefor and requests that the certificates for such shares be
issued in the name of, and delivered to,
                                    , federal taxpayer
identification number                 , whose address is
                                        
                . 
  
 In exercising this Warrant, the undersigned hereby confirms and acknowledges that the
                 New Preferred Stock Shares (as defined in the attached Warrant) are being acquired solely for the account of the undersigned and not as a nominee
for any other party, and for investment, and the undersigned will not offer, sell or otherwise dispose of any such New Preferred Stock Shares except under circumstances that will not result in a violation of the Securities Act of 1933, as amended,
or any state securities laws. 
  
 Please issue a new Warrant for
the unexercised portion of the attached Warrant in the name of, and delivered to,
                            , federal taxpayer identification number
                , whose address is
                                        
                            . 
  
 Dated:                     

  

	
	  
  

	 (Signature must conform to name of holder
 as specified
on the face of the Warrant)

	*	Insert here the number of shares as to which the Warrant is being exercised. 

  

 A-1 

 EXHIBIT B 
  

FORM OF NET ISSUE ELECTION NOTICE 
  
 (To be signed only on net issue exercise of the Warrant) 
  
 The undersigned, the holder of the within Warrant, hereby irrevocably elects to exercise this Warrant with respect to
                 New Preferred Stock Shares (as defined in the attached Warrant) of SKINMEDICA, INC., a
Delaware corporation, pursuant to the net issue election provisions set forth in Section 2.6 of the Warrant and requests that the certificates for the number of New Preferred Stock Shares issuable pursuant to said Section 2.6 after application of
the net issue election formula to such New Preferred Stock Shares be issued in the name of, and delivered to,
                            , federal taxpayer identification number
                , whose address is
                                        
                        . 
  
 In exercising this Warrant, the undersigned hereby confirms and acknowledges that the New Preferred Stock Shares are being acquired solely for the account
of the undersigned and not as a nominee for any other party, and for investment, and the undersigned will not offer, sell or otherwise dispose of any such New Preferred Stock Shares except under circumstances that will not result in a violation of
the Securities Act of 1933, as amended, or any state securities laws. 
  
 Please issue a new Warrant for the unexercised portion of the attached Warrant in the name of, and delivered to,
                            , federal taxpayer identification number
                , whose address is
                                        
                        . 
  
 Dated:                      
  

	
	  
  

	 (Signature must conform to name of holder
 as specified
on the face of the Warrant)

  

 B-1 

 Schedule to Exhibit 4.5: 
  
 The preceding form of Preferred Stock warrant was issued to the following entities and individuals in the following amounts listed below: 
  

					
	 Warrant Number

	 	 Name

	  	Number of Shares

	 WDII-1
	 	HealthCare Ventures VII, L.P.	  	279,079
	 WDII-2
	 	Perseus-Soros Biopharmaceutical Fund, LP	  	167,447
	 WDII-3
	 	Montreux Equity Partners II SBIC, L.P.	  	37,197
	 WDII-4
	 	Montreux Equity Partners III SBIC, L.P.	  	46,525
	 WDII-5
	 	CAC, LLC	  	34,884
	 WDII-6
	 	DRD Family Partnership, LP	  	34,884
	 WDII-7
	 	Apax Excelsior VI, L.P.	  	35,771
	 WDII-8
	 	Apax Excelsior VI-A C.V.	  	2,921
	 WDII-9
	 	Apax Excelsior VI-B C.V.	  	1,946
	 WDII-10
	 	Patricof Private Investment Club III, L.P.	  	1,222
	 WDII-11
	 	Domain Partners V, L.P.	  	54,527
	 WDII-12
	 	DP V Associates, L.P.	  	1,288
	 WDII-13
	 	St. Paul Venture Capital VI, LLC	  	55,815
	 WDII-14
	 	Fog City Fund, LLC	  	41,861
	 WDII-15
	 	Bio 21 Venture Capital Corporation	  	27,907
	 WDII-16
	 	Stephens, Inc. Custodian for the James Gilstrap IRA	  	8,244
	 WDII-17
	 	Hard Z Partners – Venture II	  	3,253
	 WDII-18
	 	Morris Enterprises	  	2,009
	 WDII-19
	 	Res Bright and Marilyn Bright, Trustees of the Bright Family Trust dated February 28, 2003	  	279
	 WDII-20
	 	Randall K. Simpson	  	111
	 WDII-21
	 	Cheston J. Larson	  	55

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00083-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00083-of-00352.parquet"}]]